Rayno Life Science Portfolio Notes: CPHD PCYC TMO
Biotechnology Sector Hit with Profit Taking This week's Barrons: The West Coast Was the Right Coast Wedbush ranked #1 in % change 6 mo (+12.75%), one year (+18.84%) and three year (81.05%) stock picks and Seattle's McAdams Wright Ragen scored #1 (+14.1%) in % change over 5 years. Wedbush and...
Stealth Rally Picks Up on EuroTawk From Mario Draghi
Vague talk about Monetary Actions in Europe Sparks Broad Three Day Rally It started yesterday with Draghi saying that ECB actions are being proposed that would reduce bond yields in Italy and Spain. Draghi will hold talks with Bundesbank President Jens Weidmann in the coming days with new...
Biotech Stocks Fly Over Macro Flack: ALXN, ILMN, REGN, TMO
Rayno Life Science Focus Stocks Are Strong-TMO Added Biopharmaceutical stocks continue their run today beginning with higher sales expectations for Regeneron(REGN $128) with their eye drug for macular degeneration.Regeneron raised expectation for Eyelea to $700-750 from $500-550.Total revenue...
Clinical Diagnostics Stocks Sell-Off on Cepheid (CPHD $33.25) Guidance Cut
AACC Meeting Hangover Begins With Cepheid Earnings Cuts--Stock Off 24% on Volume of 7M shares Cepheid (CPHD) a leader in molecular diagnostics, forecasted earnings of 38-42 cents a share for the year down from 50-55 cents a share on expected revenues in the range of $333-347M. Revenue for Q2...
Rayno Life Science Portfolio: Huge Year for Diagnostics and Tools Stocks
2012: Four Big Winners Up 30-40% in DX and Tools Portfolio: ABAX, EXAS, GPRO, ILMN In a volatile year with dire macro news and low growth forecasts the NASDAQ was up 10 % YTD and the Rayno Life Science Portfolio had its best year since 2010. M&A continues to play a big role and over the...